Dave Carlson

@davecarlson.bsky.social

PhD in EcoEvo. Bioinformatics & High Performance Computing. Transposon enthusiast.

I'm actually astonished at how clean this graph looks as a diagnostic for our housing ills. Note how close it is to 1 at the start. Houses per single adult or married couple.

Houses per (population over 25 - married couples)

Subtracting married couples prevents them from being counted twice, since a married couple doesn't need 2 homes, but 2 single people (ideally) do.

As the people in power destroy the mechanisms that generate inspiration in the natural world, rest assured that nothing could stop me from continuing to be a bit of a psycho on behalf of nature. If I can get more funding I'll continue empowering other nutjobs to do this work alongside me.

Asher Elbein@asherelbein.bsky.social · 2w ago

"Most of the affected employees were at National Geographic, both at the cable network as well as editorial and operations." 🫠

Very excited to see the first chapter of my PhD out on bioRxiv! It began as a rotation project and became a pivotal part of my PhD on beetles, adding a complementary macroevolutionary perspective to my second chapter on early-stage speciation in Indonesian herbivorous ladybird beetles.

bioRxiv Evolutionary Biology@biorxiv-evobio.bsky.social · 2w ago

338 coleopteran genomes reveal exceptional rearrangement variation compared to other insect orders https://www.biorxiv.org/content/10.64898/2026.07.17.739156v1

Yet another Kalshi offering that serves no legitimate economic purpose. It's not possible to make a rational bet on this without material non-public information. It's a market solely for fraud by both regulators and corporate insiders, and everyone connected to it in any way should go to prison.

Kalshi Will Offer Sports-Style Betting on Drug Trial Results

Kalshi Inc. is expanding in biotechnology by offering wagers on the outcomes of clinical trials and regulatory decisions, giving traders a more direct way to bet on key industry catalysts.

bloomberg.com

Our new genome annotation method relies almost entirely on transcriptome and alignment evidence, and as a result outperforms pretty much all other de novo pipelines. Check out the just-published paper led by Aleksey Zimin: rdcu.be/frSOg

Efficient evidence-based genome annotation with EviAnn

Nature Methods - EviAnn surpasses existing genome annotation methods by leveraging gene expression and protein sequence homology evidence to achieve higher accuracy and efficiency.

rdcu.be